FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

FORXIGA®: Safety and tolerability

Results from an extensive clinical trial programme1

MACE, its components and additional CV events in patients with a history of CVD44*

A meta-analysis of 21 Phase IIb/III studies in which 34.4% of subjects had a history of CVD (excluding hypertension) at baseline and 67.9% had hypertension.44 Studies that did not have at least one positively adjudicated event were excluded from analysis.45

MACE, its components and additional CV events in patients with a history of CVD
MACE, its components and additional CV events in patients with a history of CVD

*FORXIGA® is not indicated to reduce the risk of cardiovascular events.1